Data completeness
4/8 — Partial
SYNTOCINON (oxytocin) by Novartis is clinical pharmacology oxytocin injection (synthetic) acts on the smooth muscle of the uterus to stimulate contractions; response depends on the uterine threshold of excitability. Approved for postpartum hemorrhage, labor induction.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNTOCINON is a synthetic oxytocin injection indicated for labor induction and postpartum hemorrhage prevention. It acts on uterine smooth muscle to stimulate rhythmic contractions and increase uterine tone, with response dependent on individual uterine excitability. Unlike vasopressin, synthetic oxytocin lacks significant cardiovascular effects such as blood pressure elevation.
Pre-Launch
Pre-launch stage indicates opportunity to build brand from ground level; team will scale rapidly post-approval in obstetrics-focused commercial organization.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxytocin injection (synthetic) acts on the smooth muscle of the uterus to stimulate contractions; response depends on the uterine threshold of excitability. It exerts a selective action on the smooth musculature of the uterus, particularly toward the end of pregnancy, during…
Indications (2)
Worked on SYNTOCINON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.